(Q35911103)

11 August 2017

1 reference

title

Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis (English)

1 reference

11 August 2017

0 references

Kumar Visvanathan

2

1 reference

ORCID Public Data File 2021

author name string

Andrew D Cook

series ordinal

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Expert Opinion on Therapeutic Targets

11 August 2017

published in

1 reference

11 August 2017

volume

8

1 reference

11 August 2017

issue

5

1 reference

11 August 2017

page(s)

375-390

1 reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Basic therapy for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Anti-TNF-alpha therapies: the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

A proinflammatory role for IL-18 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Interleukins 18 and 12 synergistically upregulate interferon-gamma production by murine dendritic epidermal T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Anti-interleukin-18 therapy in murine models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Macrophage-Derived IL-18 Targeting for the Treatment of Crohns Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

GM-CSF in inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

IL-10 and its related cytokines for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

The main function of IL-2 is to promote the development of T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

CD28/CTLA-4 and CD80/CD86 families: signaling and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

T-cell co-stimulation through B7RP-1 and ICOS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Inducible costimulator is essential for collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Biological aspects of signal transduction by cell adhesion receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Inhibition of adjuvant-induced arthritis by systemic tissue inhibitor of metalloproteinases 4 gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Systems biology: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Gene expression profiles: creating new perspectives in arthritis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Microarray analysis of gene expression in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Tissue microarrays in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Mass spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Protein microarrays for gene expression and antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Protein arrays for gene expression and molecular interaction screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.375

Expression of programmed death 1 ligands by murine T cells and APC

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4049/JIMMUNOL.169.10.5538

Identifiers

DOI

10.1517/14728222.8.5.375

1 reference

11 August 2017

1 reference